Twist Bioscience (TWST) reported a fiscal Q2 net loss Monday of $0.66 per diluted share, narrowing from $0.79 a year earlier.
Analysts polled by FactSet expected a $0.58 loss.
Revenue for the quarter ended March 31 was $92.8 million, compared with $75.3 million a year earlier.
Analysts polled by FactSet expected $92 million.
The company said it expects fiscal Q3 revenue of $94 million to $97 million. Analysts polled by FactSet expect $95.5 million.
For fiscal 2025, Twist Bioscience reiterated its revenue outlook of $372 million to $379 million. Analysts polled by FactSet expect $375.8 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.